(Q42982979)

12 November 2017

title

Seroprevalence of hepatitis C virus nucleocapsid antibodies in patients with cryptogenic chronic liver disease (English)

1 reference

12 November 2017

0 references

1 reference

1 reference

1 reference

chronic liver disease

0 references

1 reference

3

1 reference

12 November 2017

Brown J

1

1 reference

12 November 2017

Dourakis S

2

1 reference

12 November 2017

Goldin R

4

1 reference

12 November 2017

Chiba J

5

1 reference

12 November 2017

Ohba H

6

1 reference

12 November 2017

Miyamura T

7

1 reference

12 November 2017

Thomas HC

8

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 February 1992

1 reference

12 November 2017

1 reference

12 November 2017

volume

15

1 reference

12 November 2017

issue

2

1 reference

12 November 2017

page(s)

175-179

1 reference

Nucleotide sequence of core and envelope genes of the hepatitis C virus genome derived directly from human healthy carriers

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840150202

An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840150202

7 January 2021

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840150202

7 January 2021

Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV).

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840150202

7 January 2021

Detection of antibody against antigen expressed by molecularly cloned hepatitis C virus cDNA: application to diagnosis and blood screening for posttransfusion hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840150202

7 January 2021

Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840150202

7 January 2021

Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840150202

7 January 2021

Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840150202

7 January 2021

Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840150202

7 January 2021

Improved serodiagnosis of hepatitis C virus infection with synthetic peptide antigen from capsid protein

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840150202

7 January 2021

Serodiagnosis of hepatitis C virus (HCV) infection with an HCV core protein molecularly expressed by a recombinant baculovirus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840150202

7 January 2021

Histologic observations in human hepatitis non-A, non-B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840150202

7 January 2021

Demonstration of viraemia patterns in haemophiliacs treated with hepatitis-C-virus-contaminated factor VIII concentrates

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840150202

7 January 2021

A long-term study of hepatitis C virus replication in non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840150202

7 January 2021

Suppression of hepatitis C virus RNA by interferon-alpha

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840150202

7 January 2021

Effect of alpha-interferon therapy on hepatitis C viraemia in community-acquired chronic non-A, non-B hepatitis: a quantitative polymerase chain reaction study.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840150202

7 January 2021

The hepatitis C virus and its relationship to the clinical spectrum of NANB hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840150202

7 January 2021

Intrafamilial transmission of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840150202

7 January 2021

Sexual transmission of hepatitis C virus and its relation with hepatitis B virus and HIV

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840150202

7 January 2021

Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840150202

7 January 2021

Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840150202

7 January 2021

Type 2 autoimmune hepatitis and hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840150202

7 January 2021

Parenterally transmitted non-A, non-B hepatitis: Virus-specific antibody response patterns in hepatitis C virus-infected chimpanzees

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840150202

7 January 2021

Randomised controlled trial of interferon alfa (lymphoblastoid interferon) in chronic non-A non-B hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840150202

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840150202

7 January 2021

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840150202

7 January 2021

A randomized controlled open study of interferon alpha-2b treatment of chronic non-A, non-B posttransfusion hepatitis: no correlation of outcome to presence of hepatitis C virus antibodies

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840150202

7 January 2021

Is the response to recombinant alpha interferon related to the presence of antibodies to hepatitis C virus in patients with chronic non-A, non-B hepatitis?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840150202

7 January 2021

Hazards of interferon therapy for HBV-seronegative chronic hepatitis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840150202

7 January 2021

Identifiers

DOI

10.1002/HEP.1840150202

1 reference

12 November 2017

1 reference